Logo der Universitätsmedizin Mainz

Hautklinik und Poliklinik

Visual Universitätsmedizin Mainz

Malignes Melanom

Diagnostik:

RB-T002: Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität

  • Status: offen 

Stadium I:

Derzeit keine aktuelle Studie

Stadium II:

Derzeit keine aktuelle Studie

Stadium III:

BNT111-01: Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD-1-refractory/relapsed, unresectable Stage III or IV melanoma

C4221023 Portside / KEYNOTE PNC92: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY 

Nach oben

Stadium IV:

Sanofi - TED15297: Eine First-in-Human-Dosiseskalations- und Dosisexpansionsstudie der Phase I zur Beurteilung der Sicherheit, Pharmakokinetik, Pharmakodynamik und antitumoralen Wirkung von intratumoral verabreichtem SAR441000 bei Patienten mit fortgeschrittenen soliden Tumoren.
A Phase 1 First-in-Human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally in patients with advanced solid tumors

GO40558: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA

EORTC 1612: Kombination einer zielgerichteten Therapie (Encorafenib und Binimetinib) mit anschließender kombinierter Immuntherapie (Ipilimumab und Nivolumab) im Vergleich zur sofortigen kombinierten Immuntherapie bei Patienten mit nicht resektablem oder metastasiertem Melanom mit BRAF-V600-Mutation: eine randomisierte Phase-II-Studie der EORTC (EBIN)

BNT111-01: Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD-1-refractory/relapsed, unresectable Stage III or IV
melanoma

Genmab-GCT1042-01: A First-in-Human, Open-label, Dose-escalation Trial with
Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects with Malignant Solid Tumors

DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial

  • Status: Rekrutierung offen

AGENUS C-800-23: Phase 2 study of botensilimab (AGEN1181) for treatment of advanced melanoma refractory to prior checkpoint inhibitor therapy.- Neue Generation von CTLA4-mAB, auch vorbehandelte Patienten

  • Status: Rekrutierung offen

C4221023 Portside / KEYNOTE PNC92: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY 

CA027-002: Phase 1/2 Study of BMS-986253 (IL-8-Ab) in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers – Blockade von IL-8 in Kombination mit Anti-PD1- und CTLA-4-Blockade, auch vorbehandelte Patienten

  • Status: Rekrutierung offen

Huyabio HBI-8000-303: Phase 3 Study of HBI-8000 Combined with Nivolumab vs. Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors – HDAC-Inhibitor in Kombination mit Anti-PD1-Blockade 

  • Status: Rekrutierung abgeschlossen

MONETTE: Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 – Inhibition der Serine/Threonine Proteinkinase in Kombination mit Anti-PD1-Blockade - auch vorbehandelte Patienten

  • Status: Rekrutierung abgeschlossen

IO102-103: Phase 3 trial of IO102-IO103 dual-antigen immunotherapeutic plus pembrolizumab versus pembrolizumab alone in unresectable or metastatic (advanced) melanoma- Kombinierter IDO-PD-L1-mAB

  • Status: Rekrutierung abgeschlossen

ANV419-101: Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma – Blockade von IL-2 in Kombination mit Anti-PD1-Blockade

  • Status: Rekrutierung abgeschlossen

C4221016 Starboard: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma – Kombination von BRAF/MEK-Blockade mit Anti-PD1-Blockade 

  • Status: Rekrutierung abgeschlossen